Literature DB >> 6703792

Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection.

J G Fortner, J S Silva, R B Golbey, E B Cox, B J Maclean.   

Abstract

In the United States, there are an estimated 5000 to 6000 new patients annually who might be candidates for major hepatic resection to treat their recurrent colon cancer. Since 1971, the program reported here has evaluated various factors that might influence the curative potential of such an approach. Sixty-five patients had a major hepatic resection from March 1971 through May 1982. Using a stepwise proportional hazard analysis, all data that had been stored in CLINFO (a data analysis system by Bolt, Beranek and Newman; Boston, MA) were evaluated for the effect of multiple variables on the survival of patients with resected hepatic metastases. Twenty-seven had a right hepatic lobectomy; 14 had extended right hepatectomy with one having the caudate lobe also removed; ten had left lobectomy, nine had left lateral segmentectomy; and five had a major hepatic resection with three-dimensional wedge excision of a metastatic deposit in the contralateral lobe. The 30-day operative mortality rate was 7% (4/58) for patients undergoing the standard major hepatic resection. It was 14% for seven patients in whom the isolation-hypothermic perfusion technique was used early in the series. In ten patients, wedge excision only was required to remove the tumor. Stage I disease is defined as tumor confined to the resected portion of the liver without invasion of major intrahepatic vessels or bile ducts. Stage II disease is regional spread and Stage III disease is metastasis to lymph nodes or extraregional sites. The 3-year survival estimate was 66% for the 37 patients with Stage I disease. The 3-year survival estimate for 13 patients with Stage II disease was 58%. Five of the nine patients with Stage III disease are presently alive from 3 to 23 months; one of the other four died at 35 months of disease. The stage of liver disease was the most significant variable in this survival analysis (p = 0.02); Dukes' classification of colorectal primary was significant at p less than 0.05. Those factors found not to be significant determinants of survival were: number of metastatic hepatic deposits, site of colon primary, age, sex, preoperative liver function tests, and CEA.

Entities:  

Mesh:

Year:  1984        PMID: 6703792      PMCID: PMC1353397          DOI: 10.1097/00000658-198403000-00010

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

1.  A retrospective study of the natural history of patients with liver metastases from colorectal cancer.

Authors:  C B Wood; C R Gillis; L H Blumgart
Journal:  Clin Oncol       Date:  1976-09

2.  Clinical management of advanced gastrointestinal cancer.

Authors:  C G Moertel
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

3.  Regional infusion chemotherapy of hepatic metastases from carcinoma of the colon.

Authors:  B Cady; R A Oberfield
Journal:  Am J Surg       Date:  1974-02       Impact factor: 2.565

4.  Factors influencing survival in patients with untreated hepatic metastases.

Authors:  B M Jaffe; W L Donegan; F Watson; J S Spratt
Journal:  Surg Gynecol Obstet       Date:  1968-07

5.  The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy.

Authors:  S Bengmark; L Hafström
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

6.  Surgical treatment of hepatic metastases from colorectal cancers.

Authors:  S M Wilson; M A Adson
Journal:  Arch Surg       Date:  1976-04

7.  Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine.

Authors:  C G Moertel; A J Schutt; R G Hahn; R J Reitemeier
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

8.  Hepatic resection for metastasis from colorectal cancer.

Authors:  F F Attiyeh; H J Wanebo; M W Stearns
Journal:  Dis Colon Rectum       Date:  1978-04       Impact factor: 4.585

9.  Major hepatic resection using vascular isolation and hypothermic perfusion.

Authors:  J G Fortner; M H Shiu; D W Kinne; D K Kim; E B Castro; R C Watson; W S Howland; E J Beattie
Journal:  Ann Surg       Date:  1974-10       Impact factor: 12.969

10.  Major hepatic resection for neoplasia: personal experience in 108 patients.

Authors:  J G Fortner; D K Kim; B J Maclean; M K Barrett; S Iwatsuki; A D Turnbull; W S Howland; E J Beattie
Journal:  Ann Surg       Date:  1978-09       Impact factor: 12.969

View more
  110 in total

Review 1.  "Vanishing liver metastases"-A real challenge for liver surgeons.

Authors:  Alex Zendel; Eylon Lahat; Yael Dreznik; Barak Bar Zakai; Rony Eshkenazy; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Differences between bipolar compression and ultrasonic devices for parenchymal transection during laparoscopic liver resection.

Authors:  Nsehniitooh A Mbah; Russell E Brown; Matthew R Bower; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2012-02       Impact factor: 3.647

3.  "Radical" abdominal cancer surgery: current state and future course.

Authors:  J G Fortner
Journal:  Jpn J Surg       Date:  1989-09

4.  Primary lymphoma of the liver showing immunohistochemical evidence of T-cell origin. Successful management by right trisegmentectomy.

Authors:  S Andreola; R A Audisio; V Mazzaferro; R Doci; L Makowka; L Gennari
Journal:  Dig Dis Sci       Date:  1988-12       Impact factor: 3.199

5.  Results of a rigorous follow-up system in colorectal cancer.

Authors:  E Wenzl; M Wunderlich; F Herbst; M Schemper; W Feil; R Rauhs; R Schiessel
Journal:  Int J Colorectal Dis       Date:  1988-08       Impact factor: 2.571

6.  Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?

Authors:  Nir Lubezky; Ravit Geva; Einat Shmueli; Richard Nakache; Joseph M Klausner; Arie Figer; Menahem Ben-Haim
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

7.  Analysis of preoperative prognostic factors for long-term survival after hepatic resection of liver metastasis of colorectal carcinoma.

Authors:  Atsushi Sasaki; Yukio Iwashita; Kohei Shibata; Toshifumi Matsumoto; Masayuki Ohta; Seigo Kitano
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

8.  Liver resection for metastatic colorectal cancer.

Authors:  S Iwatsuki; C O Esquivel; R D Gordon; T E Starzl
Journal:  Surgery       Date:  1986-10       Impact factor: 3.982

9.  Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer.

Authors:  Kuniya Tanaka; Hiroshi Shimada; Mitsuyoshi Ohta; Shinji Togo; Shuji Saitou; Shigeki Yamaguchi; Itaru Endo; Hitoshi Sekido
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

10.  Prediction of surgical resectability in patients with hepatic colorectal metastases.

Authors:  S B Vogel; W E Drane; P R Ros; S R Kerns; K I Bland
Journal:  Ann Surg       Date:  1994-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.